Molecular Diagnostics Market Share, Trend and Analysis Report 2020
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> <strong>Share</strong>, <strong>Trend</strong> <strong>and</strong><br />
<strong>Analysis</strong> <strong>Report</strong> <strong>2020</strong>: Radiant Insights, Inc<br />
The global market for molecular diagnostics is expected to reach USD 8,020.1 million by<br />
<strong>2020</strong>. Growing dem<strong>and</strong> for personalized medicine <strong>and</strong> theranostics, <strong>and</strong> the subsequent<br />
introduction of advanced cancer diagnostic technologies are expected to be key factors<br />
driving market growth over the next six years.<br />
Moreover, the growing global base of geriatric population <strong>and</strong> chronic diseases such as<br />
cancer, coupled with disease triggering lifestyle habits such as smoking <strong>and</strong> excessive<br />
alcohol consumption will positively impact market growth.<br />
<strong>Molecular</strong> diagnostic reagent products dominated the overall market, accounting for over<br />
50% of global revenue in 2013. Reagent market revenue is expected to reach USD 4,739.9<br />
million by <strong>2020</strong>, growing at a CAGR of 9.9% from 2014 to <strong>2020</strong>. High consumption rates of<br />
molecular diagnostic reagents <strong>and</strong> the growing number of research <strong>and</strong> development<br />
initiatives pertaining to the field of molecular diagnostics are two key drivers of this<br />
product segment.<br />
Read Complete <strong>Report</strong> with TOC @<br />
http://www.radiantinsights.com/research/molecular-diagnostics-market-analysisby-product-instruments-reagents-by-technology-pcr-in-situ-hybridization-chipsamp-microarrays-mass-spectrometry-sequencing-by-application-oncologypharmacogenomics-infectious-disease-genetic-testing-neurological-diseasecardiovascular-disease-<strong>and</strong>-segment-forecasts-to-<strong>2020</strong><br />
The point of care end-use market for molecular diagnostics is expected to be the fastest<br />
growing product segment, at an estimated CAGR of 13.3% from 2014 to <strong>2020</strong>, on account<br />
of factors such as the growing dem<strong>and</strong> for point of care diagnostic procedures as an<br />
effective diagnostic tool rendering rapid <strong>and</strong> accurate results <strong>and</strong> the introduction of<br />
government initiatives such as CLIA (Clinical Laboratory Improvement Amendments)<br />
waived tests.<br />
Further key findings from the study suggest:<br />
North America dominated the overall market in terms of revenue share in 2013 at 44.6%.<br />
The presence of sophisticated healthcare infrastructure, encouraging government<br />
initiatives <strong>and</strong> high patient awareness levels are some of the drivers of this market. In
addition, the presence of enhanced R&D activities in the U.S. pertaining to advanced<br />
diagnostic technologies attributes to its large market share.<br />
The Asia Pacific molecular diagnostics market is expected to grow at the fastest rate of<br />
12.7% from 2014 to <strong>2020</strong>. High unmet medical needs in disease segments such as cancer,<br />
diabetes <strong>and</strong> cardiovascular diseases <strong>and</strong> the introduction of healthcare reforms in<br />
emerging markets such as India <strong>and</strong> China are some of the factors driving regional market<br />
growth.<br />
PCR based molecular diagnostic technology market revenue was estimated to be USD<br />
2,144.3 million in 2013 <strong>and</strong> is expected to dominate the market over the next six years.<br />
Growing dem<strong>and</strong> for genetic testing as an effective tool to develop personalized medicine<br />
based products is one of the most significant growth drivers of this market.<br />
Read Complete <strong>Report</strong> with TOC @<br />
http://www.radiantinsights.com/research/molecular-diagnostics-market-analysisby-product-instruments-reagents-by-technology-pcr-in-situ-hybridization-chipsamp-microarrays-mass-spectrometry-sequencing-by-application-oncologypharmacogenomics-infectious-disease-genetic-testing-neurological-diseasecardiovascular-disease-<strong>and</strong>-segment-forecasts-to-<strong>2020</strong><br />
Oncology applications dominated the overall market in 2013, accounting for over 30% of<br />
total revenue. Unmet medical needs, high global prevalence rates of cancer <strong>and</strong> the<br />
introduction of advanced cancer diagnostic technologies such as companion diagnostics are<br />
some of the factors accounting for its large market share.<br />
Some of the key players of this market include Roche <strong>Diagnostics</strong>, Novartis, Qiagen,<br />
bioMerieux, Cepheid, Siemens Healthcare, Hologic, Becton Dickinson <strong>and</strong> Company, Abbott<br />
Laboratories <strong>and</strong> others.<br />
For the purpose of this study, Gr<strong>and</strong> View Research has segmented the global molecular<br />
diagnostics market on the basis of product <strong>and</strong> region:<br />
<strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> Product Outlook<br />
Instruments<br />
Reagents<br />
Others<br />
<strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> Technology Outlook<br />
PCR
In Situ Hybridization<br />
Chips <strong>and</strong> Microarrays<br />
Mass Spectrometry<br />
Sequencing<br />
Others<br />
<strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> Application Outlook<br />
Oncology<br />
Pharmacogenomics<br />
Infectious Disease<br />
Genetic Testing<br />
Neurological Disease<br />
Cardiovascular Disease<br />
Others<br />
Read Complete <strong>Report</strong> with TOC @<br />
http://www.radiantinsights.com/research/molecular-diagnostics-market-analysisby-product-instruments-reagents-by-technology-pcr-in-situ-hybridization-chipsamp-microarrays-mass-spectrometry-sequencing-by-application-oncologypharmacogenomics-infectious-disease-genetic-testing-neurological-diseasecardiovascular-disease-<strong>and</strong>-segment-forecasts-to-<strong>2020</strong><br />
<strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> End-User Outlook<br />
Point of Care<br />
Self Test or OTC<br />
Hospitals <strong>and</strong> Clinics<br />
<strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> Regional Outlook<br />
North America<br />
Europe<br />
Asia Pacific<br />
Rest of the World (RoW)<br />
Table of Contents<br />
Chapter 1. Executive Summary<br />
1.1. <strong>Molecular</strong> <strong>Diagnostics</strong> - Industry Summary <strong>and</strong> Critical Success Factors (CSFs)<br />
Chapter 2. <strong>Molecular</strong> <strong>Diagnostics</strong> Industry Outlook<br />
2.1. <strong>Market</strong> Segmentation
2.2. <strong>Market</strong> Size <strong>and</strong> Growth Prospects<br />
2.3. <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> Dynamics<br />
2.4. Key Opportunities Prioritized<br />
2.5. Industry <strong>Analysis</strong> - Porter's<br />
2.6. <strong>Molecular</strong> <strong>Diagnostics</strong> - Company <strong>Market</strong> <strong>Share</strong> <strong>Analysis</strong><br />
2.7. <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> PESTEL <strong>Analysis</strong>, 2012<br />
Chapter 3. <strong>Molecular</strong> <strong>Diagnostics</strong> Product Outlook<br />
Read Complete <strong>Report</strong> with TOC @<br />
http://www.radiantinsights.com/research/molecular-diagnostics-market-analysisby-product-instruments-reagents-by-technology-pcr-in-situ-hybridization-chipsamp-microarrays-mass-spectrometry-sequencing-by-application-oncologypharmacogenomics-infectious-disease-genetic-testing-neurological-diseasecardiovascular-disease-<strong>and</strong>-segment-forecasts-to-<strong>2020</strong><br />
3.1. Instruments<br />
3.2. Reagents<br />
3.3. Others<br />
Chapter 4. <strong>Molecular</strong> <strong>Diagnostics</strong> Technology Outlook<br />
4.1. PCR<br />
4.2. In Situ Hybridization<br />
4.3. Chips <strong>and</strong> Microarrays<br />
4.4. Mass Spectrometry<br />
4.5. Sequencing<br />
4.6. Others<br />
Chapter 5. <strong>Molecular</strong> <strong>Diagnostics</strong> Application Outlook
5.1. Oncology<br />
5.2. Pharmacogenomics<br />
5.3. Infectious Disease<br />
5.4. Genetic Testing<br />
5.5. Neurological Disease<br />
5.6. Cardiovascular Disease<br />
5.7. Others<br />
Chapter 6. <strong>Molecular</strong> <strong>Diagnostics</strong> End-User Outlook<br />
Read Complete <strong>Report</strong> with TOC @<br />
http://www.radiantinsights.com/research/molecular-diagnostics-market-analysisby-product-instruments-reagents-by-technology-pcr-in-situ-hybridization-chipsamp-microarrays-mass-spectrometry-sequencing-by-application-oncologypharmacogenomics-infectious-disease-genetic-testing-neurological-diseasecardiovascular-disease-<strong>and</strong>-segment-forecasts-to-<strong>2020</strong><br />
6.1. Point of Care<br />
6.2. Self Test or OTC<br />
6.3. Central Laboratories<br />
Chapter 7. <strong>Molecular</strong> <strong>Diagnostics</strong> Regional Outlook<br />
7.1. North America<br />
7.2. Europe<br />
7.3. Asia-Pacific<br />
7.4. RoW<br />
List of Tables<br />
<strong>Molecular</strong> <strong>Diagnostics</strong> - Industry Summary & Critical Success Factors (CSFs)<br />
Global <strong>Molecular</strong> <strong>Diagnostics</strong> Revenue, 2012 - <strong>2020</strong> (USD million)
Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> Revenue by Region, (USD million), 2012 - <strong>2020</strong><br />
Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> Revenue by Products, (USD million), 2012 - <strong>2020</strong><br />
Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> Revenue by Technology, (USD million), 2012 - <strong>2020</strong><br />
Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> Revenue by Application, (USD million), 2012 - <strong>2020</strong><br />
Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> Revenue by End-Use, (USD million), 2012 - <strong>2020</strong><br />
Global <strong>Molecular</strong> Diagnostic Instruments Dem<strong>and</strong>, 2012 to <strong>2020</strong> (USD million)<br />
Global <strong>Molecular</strong> Diagnostic Instruments Dem<strong>and</strong>, by Region, 2012 to <strong>2020</strong> (USD million)<br />
Global <strong>Molecular</strong> Diagnostic Reagents Dem<strong>and</strong>, 2012 to <strong>2020</strong> (USD million)<br />
Global <strong>Molecular</strong> Diagnostic Reagents Dem<strong>and</strong>, by Region, 2012 to <strong>2020</strong> (USD million)<br />
Global Other <strong>Molecular</strong> Diagnostic Products Dem<strong>and</strong>, 2012 to <strong>2020</strong> (USD million)<br />
Global Other <strong>Molecular</strong> Diagnostic Products Dem<strong>and</strong>, by Region, 2012 to <strong>2020</strong> (USD<br />
million)<br />
Global PCR based <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, 2012 to <strong>2020</strong> (USD million)<br />
Global PCR based <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, by Region, 2012 to <strong>2020</strong> (USD million)<br />
Global In Situ Hybridization based <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, 2012 to <strong>2020</strong> (USD<br />
million)<br />
Read Complete <strong>Report</strong> with TOC @<br />
http://www.radiantinsights.com/research/molecular-diagnostics-market-analysisby-product-instruments-reagents-by-technology-pcr-in-situ-hybridization-chipsamp-microarrays-mass-spectrometry-sequencing-by-application-oncologypharmacogenomics-infectious-disease-genetic-testing-neurological-diseasecardiovascular-disease-<strong>and</strong>-segment-forecasts-to-<strong>2020</strong><br />
Global In Situ Hybridization based <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, by Region, 2012 to <strong>2020</strong><br />
(USD million)<br />
Global Chips <strong>and</strong> Microarrays based <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, 2012 to <strong>2020</strong> (USD<br />
million)<br />
Global Chips <strong>and</strong> Microarrays based <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, by Region, 2012 to<br />
<strong>2020</strong> (USD million)<br />
Global Mass Spectrometry based <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, 2012 to <strong>2020</strong> (USD<br />
million)<br />
Global Mass Spectrometry based <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, by Region, 2012 to <strong>2020</strong><br />
(USD million)<br />
Global Sequencing based <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, 2012 to <strong>2020</strong> (USD million)<br />
Global Sequencing based <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, by Region, 2012 to <strong>2020</strong> (USD<br />
million)<br />
Global Other Technology based <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, 2012 to <strong>2020</strong> (USD million)<br />
Global Other Technology based <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, by Region, 2012 to <strong>2020</strong><br />
(USD million)<br />
Global <strong>Molecular</strong> Diagnostic Dem<strong>and</strong> for Oncology, 2012 to <strong>2020</strong> (USD million)<br />
Global <strong>Molecular</strong> Diagnostic Dem<strong>and</strong> for Oncology, by Region, 2012 to <strong>2020</strong> (USD million)<br />
Global <strong>Molecular</strong> Diagnostic Dem<strong>and</strong> for Pharmacogenomics, 2012 to <strong>2020</strong> (USD million)
Global <strong>Molecular</strong> Diagnostic Dem<strong>and</strong> for Pharmacogenomics, by Region, 2012 to <strong>2020</strong><br />
(USD million)<br />
Global <strong>Molecular</strong> Diagnostic Dem<strong>and</strong> for Infectious Disease, 2012 to <strong>2020</strong> (USD million)<br />
Global <strong>Molecular</strong> Diagnostic Dem<strong>and</strong> for Infectious Disease, by Region, 2012 to <strong>2020</strong> (USD<br />
million)<br />
Global <strong>Molecular</strong> Diagnostic Dem<strong>and</strong> for Genetic Testing, 2012 to <strong>2020</strong> (USD million)<br />
Global <strong>Molecular</strong> Diagnostic Dem<strong>and</strong> for Genetic Testing, by Region, 2012 to <strong>2020</strong> (USD<br />
million)<br />
Global <strong>Molecular</strong> Diagnostic Dem<strong>and</strong> for Neurological Disease, 2012 to <strong>2020</strong> (USD million)<br />
Global <strong>Molecular</strong> Diagnostic Dem<strong>and</strong> for Neurological Disease, by Region, 2012 to <strong>2020</strong><br />
(USD million)<br />
Global <strong>Molecular</strong> Diagnostic Dem<strong>and</strong> for Cardiovascular Disease, 2012 to <strong>2020</strong> (USD<br />
million)<br />
Global <strong>Molecular</strong> Diagnostic Dem<strong>and</strong> for Cardiovascular Disease, by Region, 2012 to <strong>2020</strong><br />
(USD million)<br />
Read Complete <strong>Report</strong> with TOC @<br />
http://www.radiantinsights.com/research/molecular-diagnostics-market-analysisby-product-instruments-reagents-by-technology-pcr-in-situ-hybridization-chipsamp-microarrays-mass-spectrometry-sequencing-by-application-oncologypharmacogenomics-infectious-disease-genetic-testing-neurological-diseasecardiovascular-disease-<strong>and</strong>-segment-forecasts-to-<strong>2020</strong><br />
Global <strong>Molecular</strong> Diagnostic Dem<strong>and</strong> for Other Applications, 2012 to <strong>2020</strong> (USD million)<br />
Global <strong>Molecular</strong> Diagnostic Dem<strong>and</strong> for Other Applications, by Region, 2012 to <strong>2020</strong> (USD<br />
million)<br />
Global <strong>Molecular</strong> Diagnostic Dem<strong>and</strong> for Point of Care, 2012 to <strong>2020</strong> (USD million)<br />
Global <strong>Molecular</strong> Diagnostic Dem<strong>and</strong> for Point of Care, by Region, 2012 to <strong>2020</strong> (USD<br />
million)<br />
Global <strong>Molecular</strong> Diagnostic Dem<strong>and</strong> for Self Test or OTC, 2012 to <strong>2020</strong> (USD million)<br />
Global <strong>Molecular</strong> Diagnostic Dem<strong>and</strong> for Self Test or OTC, by Region, 2012 to <strong>2020</strong> (USD<br />
million)<br />
Global <strong>Molecular</strong> Diagnostic Dem<strong>and</strong> for Central Laboratories, 2012 to <strong>2020</strong> (USD million)<br />
Global <strong>Molecular</strong> Diagnostic Dem<strong>and</strong> for Central Laboratories, by Region, 2012 to <strong>2020</strong><br />
(USD million)<br />
North America <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, 2012 to <strong>2020</strong> (USD million)<br />
North America <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, by Product, 2012 to <strong>2020</strong> (USD million)<br />
North America <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, by Technology, 2012 to <strong>2020</strong> (USD million)<br />
North America <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, by Application, 2012 to <strong>2020</strong> (USD million)<br />
North America <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, by End-Use, 2012 to <strong>2020</strong> (USD million)<br />
Europe <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, 2012 to <strong>2020</strong> (USD million)<br />
Europe <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, by Product, 2012 to <strong>2020</strong> (USD million)<br />
Europe <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, by Technology, 2012 to <strong>2020</strong> (USD million)<br />
Europe <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, by Application, 2012 to <strong>2020</strong> (USD million)
Europe <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, by End-Use, 2012 to <strong>2020</strong> (USD million)<br />
Asia Pacific <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, 2012 to <strong>2020</strong> (USD million)<br />
Asia Pacific <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, by Product, 2012 to <strong>2020</strong> (USD million)<br />
Asia Pacific <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, by Technology, 2012 to <strong>2020</strong> (USD million)<br />
Asia Pacific <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, by Application, 2012 to <strong>2020</strong> (USD million)<br />
Asia Pacific <strong>Molecular</strong> <strong>Diagnostics</strong> Dem<strong>and</strong>, by End-Use, 2012 to <strong>2020</strong> (USD million)<br />
RoW <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, 2012 to <strong>2020</strong> (USD million)<br />
RoW <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, by Product, 2012 to <strong>2020</strong> (USD million)<br />
RoW <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, by Technology, 2012 to <strong>2020</strong> (USD million)<br />
RoW <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, by Application, 2012 to <strong>2020</strong> (USD million)<br />
RoW <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, by End-Use, 2012 to <strong>2020</strong> (USD million)<br />
List of Figures<br />
<strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> Segmentation<br />
Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> Revenue, 2012 - <strong>2020</strong><br />
<strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> Dynamics<br />
Global population base over the age group of 60 years, 2010 <strong>and</strong> 2017 (million)<br />
<strong>Molecular</strong> <strong>Diagnostics</strong> Company <strong>Market</strong> <strong>Share</strong> <strong>Analysis</strong>, 2012<br />
Read Complete <strong>Report</strong> with TOC @<br />
http://www.radiantinsights.com/research/molecular-diagnostics-market-analysisby-product-instruments-reagents-by-technology-pcr-in-situ-hybridization-chipsamp-microarrays-mass-spectrometry-sequencing-by-application-oncologypharmacogenomics-infectious-disease-genetic-testing-neurological-diseasecardiovascular-disease-<strong>and</strong>-segment-forecasts-to-<strong>2020</strong><br />
Key Opportunities Prioritized<br />
Industry <strong>Analysis</strong> - Porter's<br />
<strong>Molecular</strong> <strong>Diagnostics</strong> PESTEL <strong>Analysis</strong>, 2012<br />
Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> <strong>Share</strong>, by Product, 2012 & <strong>2020</strong><br />
Global <strong>Molecular</strong> Diagnostic Instruments Dem<strong>and</strong>, 2012 to <strong>2020</strong> (USD million)<br />
Global <strong>Molecular</strong> Diagnostic Reagents Dem<strong>and</strong>, 2012 to <strong>2020</strong> (USD million)<br />
Global Other <strong>Molecular</strong> Diagnostic Products Dem<strong>and</strong>, 2012 to <strong>2020</strong> (USD million)<br />
Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> <strong>Share</strong>, by Technology, 2012 & <strong>2020</strong><br />
Global PCR based <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, 2012 to <strong>2020</strong> (USD million)<br />
Global In Situ Hybridization based <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, 2012 to <strong>2020</strong> (USD<br />
million)<br />
Global Chips <strong>and</strong> Microarrays based <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, 2012 to <strong>2020</strong> (USD<br />
million)<br />
Global Mass Spectrometry based <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, 2012 to <strong>2020</strong> (USD<br />
million)<br />
Global Sequencing based <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, 2012 to <strong>2020</strong> (USD million)<br />
Global Other Technology based <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, 2012 to <strong>2020</strong> (USD million)
Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> <strong>Share</strong>, by Application, 2012 & <strong>2020</strong><br />
Global <strong>Molecular</strong> Diagnostic Dem<strong>and</strong> for Oncology, 2012 to <strong>2020</strong> (USD million)<br />
Global <strong>Molecular</strong> Diagnostic Dem<strong>and</strong> for Pharmacogenomics, 2012 to <strong>2020</strong> (USD million)<br />
Global <strong>Molecular</strong> Diagnostic Dem<strong>and</strong> for Infectious Disease, 2012 to <strong>2020</strong> (USD million)<br />
Global <strong>Molecular</strong> Diagnostic Dem<strong>and</strong> for Genetic Testing, 2012 to <strong>2020</strong> (USD million)<br />
Global <strong>Molecular</strong> Diagnostic Dem<strong>and</strong> for Neurological Disease, 2012 to <strong>2020</strong> (USD million)<br />
Global <strong>Molecular</strong> Diagnostic Dem<strong>and</strong> for Cardiovascular Disease, 2012 to <strong>2020</strong> (USD<br />
million)<br />
Global <strong>Molecular</strong> Diagnostic Dem<strong>and</strong> for Other Applications, 2012 to <strong>2020</strong> (USD million)<br />
Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> <strong>Share</strong>, by End-Use, 2012 & <strong>2020</strong><br />
Global <strong>Molecular</strong> Diagnostic Dem<strong>and</strong> for Point of Care, by Region, 2012 to <strong>2020</strong> (USD<br />
million)<br />
Global <strong>Molecular</strong> Diagnostic Dem<strong>and</strong> for Self Test or OTC, by Region, 2012 to <strong>2020</strong> (USD<br />
million)<br />
Read Complete <strong>Report</strong> with TOC @<br />
http://www.radiantinsights.com/research/molecular-diagnostics-market-analysisby-product-instruments-reagents-by-technology-pcr-in-situ-hybridization-chipsamp-microarrays-mass-spectrometry-sequencing-by-application-oncologypharmacogenomics-infectious-disease-genetic-testing-neurological-diseasecardiovascular-disease-<strong>and</strong>-segment-forecasts-to-<strong>2020</strong><br />
Global <strong>Molecular</strong> Diagnostic Dem<strong>and</strong> for Central Laboratories, 2012 to <strong>2020</strong> (USD million)<br />
Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> <strong>Share</strong>, by Region, 2012 & <strong>2020</strong><br />
North America <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, 2012 to <strong>2020</strong> (USD million)<br />
North America <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, by Product, 2012 to <strong>2020</strong> (USD million)<br />
North America <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, by Technology, 2012 to <strong>2020</strong> (USD million)<br />
North America <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, by Application, 2012 to <strong>2020</strong> (USD million)<br />
North America <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, by End-Use, 2012 to <strong>2020</strong> (USD million)<br />
Europe <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, 2012 to <strong>2020</strong> (USD million)<br />
Europe <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, by Product, 2012 to <strong>2020</strong> (USD million)<br />
Europe <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, by Technology, 2012 to <strong>2020</strong> (USD million)<br />
Europe <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, by Application, 2012 to <strong>2020</strong> (USD million)<br />
Europe <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, by End-Use, 2012 to <strong>2020</strong> (USD million)<br />
Asia Pacific <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, 2012 to <strong>2020</strong> (USD million)<br />
Asia Pacific <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, by Product, 2012 to <strong>2020</strong> (USD million)<br />
Asia Pacific <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, by Technology, 2012 to <strong>2020</strong> (USD million)<br />
Asia Pacific <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, by Application, 2012 to <strong>2020</strong> (USD million)<br />
Asia Pacific <strong>Molecular</strong> <strong>Diagnostics</strong> Dem<strong>and</strong>, by End-Use, 2012 to <strong>2020</strong> (USD million)<br />
RoW <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, 2012 to <strong>2020</strong> (USD million)<br />
RoW <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, by Product, 2012 to <strong>2020</strong> (USD million)<br />
RoW <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, by Technology, 2012 to <strong>2020</strong> (USD million)<br />
RoW <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, by Application, 2012 to <strong>2020</strong> (USD million)<br />
RoW <strong>Molecular</strong> Diagnostic Dem<strong>and</strong>, by End-Use, 2012 to <strong>2020</strong> (USD million)
About Us<br />
Radiant Insights is a platform for companies looking to meet their market research <strong>and</strong><br />
business intelligence requirements. We assist <strong>and</strong> facilitate organizations <strong>and</strong> individuals<br />
procure market research reports, helping them in the decision making process. We have a<br />
comprehensive collection of reports, covering over 40 key industries <strong>and</strong> a host of micro<br />
markets. In addition to over extensive database of reports, our experienced research<br />
coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups<br />
<strong>and</strong> customized research solutions.<br />
For more information visit: Radiant Insights<br />
Contact:<br />
Michelle Thoras<br />
Corporate Sales Specialist, USA<br />
Radiant Insights, Inc<br />
Phone: 1-415-349-0054<br />
Toll Free: 1-888-202-9519<br />
Email: sales@radiantinsights.com<br />
Blog URL: http://sagarkadam.kinja.com/
Change language